Comprehensive molecular portraits of human breast tumours.

Cancer genome landscapes. Science (2013) 25.33

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal (2013) 19.54

Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91

Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29

The somatic genomic landscape of glioblastoma. Cell (2013) 11.73

The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68

Comprehensive molecular characterization of urothelial bladder carcinoma. Nature (2014) 8.48

Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73

Emerging landscape of oncogenic signatures across human cancers. Nat Genet (2013) 6.48

Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science (2014) 5.25

APOBEC3B is an enzymatic source of mutation in breast cancer. Nature (2013) 5.18

Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72

An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet (2013) 4.69

Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol (2015) 4.38

-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol (2015) 4.31

RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell (2015) 4.30

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell (2014) 4.17

Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet (2013) 4.03

ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol (2014) 4.00

Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96

Tumour heterogeneity in the clinic. Nature (2013) 3.92

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85

Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell (2013) 3.61

Proteogenomic characterization of human colon and rectal cancer. Nature (2014) 3.61

The landscape of long noncoding RNAs in the human transcriptome. Nat Genet (2015) 3.58

Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clin Cancer Res (2014) 3.50

How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst (2014) 3.43

Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35

Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell (2013) 3.33

Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell (2013) 3.26

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. Cell Rep (2014) 3.24

Network-based stratification of tumor mutations. Nat Methods (2013) 3.12

Interplay between the cancer genome and epigenome. Cell (2013) 3.05

Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature (2016) 3.05

Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol (2014) 3.04

Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet (2015) 3.02

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00

Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res (2014) 2.92

Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet (2014) 2.91

Genome-wide analysis of noncoding regulatory mutations in cancer. Nat Genet (2014) 2.86

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature (2014) 2.85

XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature (2014) 2.84

GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood (2013) 2.82

Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature (2014) 2.81

Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nat Rev Cancer (2013) 2.60

Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56

Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55

Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50

Origins of metastatic traits. Cancer Cell (2013) 2.49

The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. Nat Commun (2014) 2.48

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48

Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports (2013) 2.47

Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. Nat Med (2014) 2.47

FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer (2014) 2.46

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A (2014) 2.46

ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science (2014) 2.42

Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42

Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell (2015) 2.39

Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers. Proc Natl Acad Sci U S A (2015) 2.35

Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A (2013) 2.29

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget (2015) 2.28

DGIdb: mining the druggable genome. Nat Methods (2013) 2.26

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol (2014) 2.25

A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun (2014) 2.25

Deciphering and reversing tumor immune suppression. Immunity (2013) 2.24

Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24

The shaping and functional consequences of the microRNA landscape in breast cancer. Nature (2013) 2.22

The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell (2014) 2.21

Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. J Mol Diagn (2013) 2.20

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res (2014) 2.18

A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol (2014) 2.12

Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature (2016) 2.11

PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res (2014) 2.06

Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature (2015) 2.04

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res (2014) 2.03

GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol (2013) 2.03

Forkhead box proteins: tuning forks for transcriptional harmony. Nat Rev Cancer (2013) 2.02

Diverse mechanisms of somatic structural variations in human cancer genomes. Cell (2013) 2.00

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell (2014) 2.00

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol (2015) 1.99

Cancer evolution is associated with pervasive positive selection on globally expressed genes. PLoS Genet (2014) 1.94

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92

Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer (2013) 1.92

The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal (2013) 1.92

The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell (2015) 1.91

Tumour angiogenesis regulation by the miR-200 family. Nat Commun (2013) 1.90

MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89

SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. PLoS Comput Biol (2014) 1.88

TCGA-assembler: open-source software for retrieving and processing TCGA data. Nat Methods (2014) 1.86

Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. Nat Genet (2013) 1.80

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature (2014) 1.79

GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. Genome Res (2012) 1.77

CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell (2015) 1.77

The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell (2013) 1.75

SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS One (2013) 1.74

Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol (2014) 1.74

Molecular portraits of human breast tumours. Nature (2000) 94.14

Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88

Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02

Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res (2010) 25.85

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01

Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature (2012) 20.47

Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature (2009) 18.08

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell (2006) 16.05

Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 14.50

mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45

The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature (2012) 11.91

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res (2010) 10.90

Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33

Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet (2011) 8.53

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48

Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (2010) 8.44

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12

The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82

Mutual exclusivity analysis identifies oncogenic network modules. Genome Res (2011) 7.22

Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 6.65

Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A (2010) 5.60

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39

Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell (2008) 5.38

Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. Nat Genet (1997) 4.92

High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43

Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30

Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95

Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92

Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Nat Genet (1997) 3.91

Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell (2010) 3.81

The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res (2008) 3.80

Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53

DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene (2001) 3.28

A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25

Molecular stratification of triple-negative breast cancers. Oncologist (2011) 2.81

Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proc Natl Acad Sci U S A (2010) 2.67

Gene expression patterns associated with p53 status in breast cancer. BMC Cancer (2006) 2.61

Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38

A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS One (2009) 2.29

Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat (2011) 2.23

CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis. Cancer Cell (2009) 2.17

Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Mol Cell Biol (2010) 1.86

Gene profiling approaches help to define the specific functions of retinoblastoma family in epidermis. Mol Carcinog (2008) 1.68

Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13

Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature (2015) 5.50

Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91

Characterization of HPV and host genome interactions in primary head and neck cancers. Proc Natl Acad Sci U S A (2014) 1.37

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep (2017) 0.76

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep (2017) 0.75